Other · 2026
Review of what is known about mescaline's safety and therapeutic potential in humans
- Original title
- Psychedelic Therapy: A Primer for Primary Care Clinicians-Mescaline.
- Authors
- Tabaac BJ, Shinozuka K, Fadel M, et al.
- Journal
- American journal of therapeutics, 2026
- Molecules
- Mescaline
- Conditions
- Healthy volunteers
- Evidence grade
- Low
- Source
- Read the original paper
The question
What do we currently know about mescaline as a possible psychiatric treatment, and how safe is it in humans?
What they did
This is a review article written for primary care clinicians. The authors summarize existing human research on mescaline, a classic psychedelic found in certain cacti with a long history of Indigenous ceremonial use. They describe how it works in the brain, what randomized placebo-controlled studies in healthy volunteers have shown, and where the gaps in knowledge lie.
What they found
The authors report that mescaline works mainly by activating the serotonin 2A receptor in the brain. Randomized, placebo-controlled studies in healthy participants found that its subjective effects increase with dose, alongside moderate and temporary stimulation of the body’s automatic functions such as heart rate and blood pressure, with no serious medical complications under controlled conditions. Side effects were generally short-lived and resolved on their own, and pooled safety analyses plus observational data pointed to a generally favourable safety profile in carefully screened people. The authors stress that there are no controlled clinical trials of mescaline in patients with psychiatric conditions.
The fine print
This is a review, not a new study, and the abstract reports no participant numbers, doses or effect sizes. Nearly all modern safety data come from healthy volunteers who were screened beforehand, so safety in people with heart, metabolic or psychiatric conditions is unknown. The long duration of mescaline’s effects and its long-term safety in therapy settings remain unstudied. This summary is based on the abstract only.
What it means
Mescaline appears reasonably well tolerated by healthy, screened volunteers in controlled research settings, but there is currently no clinical trial evidence that it treats any psychiatric condition.
Evidence grade: Low. A narrative review written as a primer for clinicians; it summarizes existing studies rather than reporting new data or a systematic pooled analysis.
This summary is based on the study’s published abstract.